ויפנד 200 מג אבקה להזרקה إسرائيل - العبرية - Ministry of Health

ויפנד 200 מג אבקה להזרקה

pfizer pfe pharmaceuticals israel ltd - voriconazole - אבקה להכנת תמיסה לאינפוזיה - voriconazole 200 mg/vial - voriconazole - voriconazole - treatment of :- invasive aspergillosis fluconazole-resistant serious invasive candida infections (including c. krusei) , - serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.

ויפנד 200 מג אבקה להכנת תמיסה לעירוי إسرائيل - العبرية - Ministry of Health

ויפנד 200 מג אבקה להכנת תמיסה לעירוי

pfizer pfe pharmaceuticals israel ltd - voriconazole - אבקה להכנת תמיסה לאינפוזיה - voriconazole 200 mg/vial - voriconazole - voriconazole - treatment of :- invasive aspergillosis fluconazole-resistant serious invasive candida infections (including c. krusei) , - serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.

ויפנד 40 מגמל אבקה להכנת תרחיף למתן דרך הפה إسرائيل - العبرية - Ministry of Health

ויפנד 40 מגמל אבקה להכנת תרחיף למתן דרך הפה

pfizer pfe pharmaceuticals israel ltd - voriconazole - אבקה להכנת תרחיף - voriconazole 40 mg/ml - voriconazole - voriconazole - treatment of : invasive aspergillosis, fluconazole-resistant serious invasive candida infections (including c. krusei) , serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to immunocompromised patients with progressive possibly life-threatening infections. treatment of candidemia in non neutropenic patients.

נוקספיל תרחיף إسرائيل - العبرية - Ministry of Health

נוקספיל תרחיף

merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti

נוקספיל תרחיף إسرائيل - العبرية - Ministry of Health

נוקספיל תרחיף

merck sharp & dohme israel ltd - posaconazole - תרחיף - posaconazole 40 mg/ml - posaconazole - posaconazole - noxafil is indicated for use in the treatment of the following fungal infections in adults : - invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products - fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b - chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole - coccidioidomycosis in patients with disease that is refractory to amphotericin b itraconazole or fluconazole or in patients who are intolerant of these medicinal products - oropharyngeal candidiasis : as first - line therapy in patients who have severe disease or are immunocompromised in whom response to topical therapy is expected to be poor. refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective anti

קרטוספור إسرائيل - العبرية - Ministry of Health

קרטוספור

padagis israel agencies ltd, israel - bifonazole; urea - משחה - urea 40 %; bifonazole 1 % - bifonazole - bifonazole - for nail stripping and antifungal treatment of fungal infections of the finger nails and toe nails.

אגיספור לפטרת הציפורניים إسرائيل - العبرية - Ministry of Health

אגיספור לפטרת הציפורניים

perrigo israel pharmaceuticals ltd - bifonazole; urea - משחה - bifonazole 1 %; urea 40 % - imidazole and triazole derivatives - for nail stripping and antifungal treatment of fungal infections of the finger nails and toe nails.

קלטרה תמיסה לשתייה إسرائيل - العبرية - Ministry of Health

קלטרה תמיסה לשתייה

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - תמיסה (פומי) - ritonavir 20 mg/ml; lopinavir 80 mg/ml - ritonavir - ritonavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.

קלטרה 100 מג25 מג טבליות إسرائيل - العبرية - Ministry of Health

קלטרה 100 מג25 מג טבליות

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - טבליות מצופות פילם - lopinavir 100 mg; ritonavir 25 mg - ritonavir - ritonavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infections.

קלטרה 200 מג50 מג טבליות إسرائيل - العبرية - Ministry of Health

קלטרה 200 מג50 מג טבליות

abbvie biopharmaceuticals ltd, israel - lopinavir; ritonavir - טבליות מצופות פילם - ritonavir 50 mg; lopinavir 200 mg - lopinavir - lopinavir - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection.